A phase 1, randomized, placebo-controlled, double-blinded study to determine safety, tolerability, and pharmacokinetics of GDC-0276 in healthy volunteers

Trial Profile

A phase 1, randomized, placebo-controlled, double-blinded study to determine safety, tolerability, and pharmacokinetics of GDC-0276 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2017

At a glance

  • Drugs GDC 0276 (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 08 Jan 2017 Status changed from recruiting to completed, as reported by a Xenon Pharmaceuticals media release.
    • 10 Nov 2015 According to a Xenon Pharmaceuticals media release, patient enrolment in this trial is expected to be completed by the end of 2015.
    • 28 May 2015 According to Xenon Pharmaceuticals media release, patient enrollment is expected to complete in the second half of 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top